Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.

Published on Aug 21, 2021in Journal of Cardiac Failure3.435
· DOI :10.1016/J.CARDFAIL.2021.07.021
Robert L. Owens (UCLA: University of California, Los Angeles), Kade Birkeland5
Estimated H-index: 5
(Cedars-Sinai Medical Center)
+ 5 AuthorsRaj M. Khandwalla5
Estimated H-index: 5
(Cedars-Sinai Medical Center)
Abstract null null Background null Heart failure and sleep-disordered breathing have been increasingly recognized as co-occurring conditions. Their bidirectional relationship warrants investigation into whether heart failure therapy improves sleep and sleep-disordered breathing. We sought to explore the effect of treatment with sacubitril/valsartan on sleep-related endpoints from the AWAKE-HF study. null null null Methods and Results null AWAKE-HF was a randomized, double-blind study conducted in 23 centers in the United States. Study participants with heart failure with reduced rejection fraction and New York Heart Association class II or III symptoms were randomly assigned to receive treatment with either sacubitril/valsartan or enalapril. All endpoints were assessed at baseline and after 8 weeks of treatment. Portable sleep-monitoring equipment was used to measure the apnea-hypopnea index, including obstructive and central events. Total sleep time, wake after sleep onset and sleep efficiency were exploratory measures assessed using wrist actigraphy. null null null The results were as follows null 140 patients received treatment in the double-blind phase (sacubitril/valsartan, n = 70; enalapril, n = 70). At baseline, 39% and 40% of patients randomly assigned to receive sacubitril/valsartan or enalapril, respectively, presented with undiagnosed, untreated, moderate-to-severe sleep-disordered breathing (≥ 15 events/h), and nearly all had obstructive sleep apnea. After 8 weeks of treatment, the mean 4% apnea-hypopnea index changed minimally from 16.3/h to 15.2/h in the sacubitril/valsartan group and from 16.8/h to 17.6/h in the enalapril group. Mean total sleep time was long at baseline and decreased only slightly in both treatment groups at week 8 (–14 and –11 minutes for sacubitril/valsartan and enalapril, respectively), with small changes in wake after sleep onset and sleep efficiency in both groups. null null null Conclusions null In a cohort of patients with heart failure with reduced rejection fraction who met prescribing guidelines for sacubitril/valsartan, one-third had undiagnosed moderate-to-severe obstructive sleep apnea. The addition of sacubitril/valsartan therapy did not significantly improve sleep-disordered breathing or sleep duration or efficiency. Patients who meet indications for treatment with sacubitril/valsartan should be evaluated for sleep-disordered breathing.
📖 Papers frequently viewed together
16 Citations
1 Citations
25 Citations
#1Khalil Anchouche (MUHC: McGill University Health Centre)
#2Malik Elharram (MUHC: McGill University Health Centre)H-Index: 6
Last. Mona Fiuzat (Duke University)H-Index: 45
view all 16 authors...
Abstract null null Background null Actigraphy-based measurements of physiologic parameters may enable design of patient-centric heart failure (HF) clinical trials. Recently, the Heart Failure Collaboratory (HFC) focused on recommendations for meaningful change and use of actigraphy as an endpoint in HF clinical trials. We aimed to evaluate randomized controlled trials (RCTs) that have quantified the impact of HF interventions using actigraphy. null null null Methods null Using a scoping review s...
1 CitationsSource
#1Raj M. Khandwalla (Cedars-Sinai Medical Center)H-Index: 5
#2Daniel Grant (Novartis)H-Index: 3
view all 8 authors...
AWAKE-HF evaluated the effect of the initiation of sacubitril/valsartan versus enalapril on activity and sleep using actigraphy in patients who have heart failure with reduced ejection fraction (HFrEF). In this randomized, double-blind study, patients with HFrEF (n = 140) were randomly assigned to sacubitril/valsartan or enalapril for 8 weeks, followed by an 8-week open-label phase with sacubitril/valsartan. Primary endpoint was change from baseline in mean activity counts during the most active...
3 CitationsSource
#1Claudio Passino (Sant'Anna School of Advanced Studies)H-Index: 62
#2Paolo SciarroneH-Index: 4
Last. Alberto Giannoni (Sant'Anna School of Advanced Studies)H-Index: 21
view all 8 authors...
Abstract Background To assess the impact of sacubitril-valsartan on apneic burden in patients with heart failure with reduced ejection fraction (HFrEF), 51 stable HFrEF patients planned for switching from an ACE-i/ARB to sacubitril-valsartan were prospectively enrolled. Methods and results At baseline and after 6 months of treatment, all patients underwent echocardiography, 24-h cardiorespiratory monitoring, neurohormonal evaluation, and cardiopulmonary exercise testing. At baseline 29% and 65% ...
1 CitationsSource
#1Chayakrit Krittanawong (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 14
#2Anirudh Kumar (Cleveland Clinic)H-Index: 9
Last. Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 167
view all 8 authors...
ABSTRACT The 2016 American Heart Association Scientific Statement on sleep duration and cardiovascular risk suggested that optimal sleep duration is critical for cardiovascular health, with both long and short sleep duration associated with adverse health outcomes. We examined the relation between sleep duration and cardiovascular health among the general population in the United States from 2005 to 2016. We sought to investigate associations between sleep duration and the prevalence of coronary...
12 CitationsSource
#1Li-Wei LiuH-Index: 1
#2Po-Ching WuH-Index: 1
Last. Ching-Chang FangH-Index: 1
view all 5 authors...
Background: The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to improve outcomes of cardiac death and hospitalization due to heart failure in patients with heart failure and reduced ejection fraction (HFrEF). However, data on improvements in ejection fraction after using sacubitril/valsartan are still lacking in Taiwan. Methods: We conducted this prospective, single armed, observation cohort study to evaluate changes in left ventricular ejection fraction (LVEF) in pati...
3 CitationsSource
#1Guillaume Marquis-Gravel (Durham University)H-Index: 5
#2Matthew T. Roe (Durham University)H-Index: 104
Last. Eric D. PetersonH-Index: 78
view all 30 authors...
The complexity and costs associated with traditional randomized, controlled trials have increased exponentially over time, and now threaten to stifle the development of new drugs and devices. Never...
28 CitationsSource
#1Michael V. Genuardi (University of Pittsburgh)H-Index: 6
#2Rachel P. Ogilvie (University of Pittsburgh)H-Index: 10
Last. Sanjay R. Patel (University of Pittsburgh)H-Index: 73
view all 7 authors...
Background Short sleep may be a risk factor for atrial fibrillation. However, previous investigations have been limited by lack of objective sleep measurement and small sample size. We sought to determine the association between objectively measured sleep duration and atrial fibrillation. Methods All 31,079 adult patients undergoing diagnostic polysomnography from 1999 to 2015 at multiple sites within a large hospital network were identified from electronic medical records. Prevalent atrial fibr...
12 CitationsSource
#1Sangchoon Jeon (Yale University)H-Index: 25
#2Samantha Conley (Yale University)H-Index: 9
Last. Nancy S. Redeker (Yale University)H-Index: 34
view all 3 authors...
: Wrist-actigraphy is often used to measure sleep characteristics in a variety of populations, but discrepancies between actigraphic and polysomnographic measures have been noted in populations experiencing poor sleep quality. The purpose of this study is to examine the discrepancy between these measures and risk factors for discrepancy in people with heart failure using a novel index. We used sleep measures simultaneously recorded by actigraphy and polysomnography, and clinical data from a cros...
8 CitationsSource
#1R. Nisha Aurora (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 17
#2Susheel P. Patil (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 27
Last. Naresh M. Punjabi (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 32
view all 3 authors...
Background Sleep apnea is an underdiagnosed condition in patients with heart failure. Efficient identification of sleep apnea is needed, as treatment may improve heart failure–related outcomes. Currently, use of portable sleep monitoring in hospitalized patients and those at risk for central sleep apnea is discouraged. This study examined whether portable sleep monitoring with respiratory polygraphy can accurately diagnose sleep apnea in patients hospitalized with decompensated heart failure. Me...
19 CitationsSource
#1Henrik Fox (RUB: Ruhr University Bochum)H-Index: 13
#2Thomas BitterH-Index: 26
Last. Olaf OldenburgH-Index: 32
view all 4 authors...
Sleep-disordered breathing (SDB) is highly prevalent in patients with heart failure (HF), and is known to be associated with a worse prognosis. The severity of central sleep apnea is thought to mirror
9 CitationsSource
Cited By0